Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comorbid LUTS and erectile dysfunction: optimizing their management.

Jed Kaminetsky1

  • 1Department of Urology, New York University School of Medicine, New York, NY 10016, USA. jckammd@att.net

Current Medical Research and Opinion
|February 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease.

The Journal of urology·2026
Same author

12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.

The Journal of urology·2025
Same author

Reply by Authors.

The Journal of urology·2025
Same author

Reply by Authors.

The Journal of urology·2025
Same author

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.

The Journal of urology·2025
Same author

Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

The journal of sexual medicine·2025

Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are common in older men. Treating LUTS may improve ED, but caution is advised when combining medications due to potential side effects.

Area of Science:

  • Urology
  • Men's Health
  • Sexual Medicine

Background:

  • Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are highly prevalent in men over 50.
  • These conditions negatively impact sexual function and quality of life, especially when comorbid.
  • LUTS is an independent risk factor for ED, in addition to age.

Purpose of the Study:

  • To discuss the relationship between ED and LUTS.
  • To outline diagnostic workup for these conditions.
  • To explore current treatment options and their effects on affected men.

Main Methods:

  • Literature search of Medline, Cochrane reviews, and American Urological Association abstracts (1980-2006).
  • Keywords included BPH, LUTS, ED, sexual dysfunction, and various drug and treatment classes.

Related Experiment Videos

  • The article is not a systematic review due to the volume of literature.

    • Main Results:

    • Alpha1-adrenergic receptor (alpha1-AR) antagonists effectively treat LUTS with low sexual side-effect risk and may improve sexual function.
    • Phosphodiesterase type 5 inhibitors (PDE-5s) are first-line for ED.
    • Combining alpha1-AR antagonists and PDE-5s for comorbid LUTS and ED requires caution due to potential vasodilatory adverse events.

    Conclusions:

    • Optimal management involves screening for comorbid LUTS and ED.
    • Treatment selection should minimize both vasodilatory and sexual side-effects.
    • Integrated treatment approaches can improve quality of life for affected men.